Patents Examined by Laura B Goddard
  • Anti-PD-L1 antibody and IL-7 fusions
    Patent number: 11401331
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof
    Patent number: 11396544
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Compositions and methods for treating multiple myeloma
    Patent number: 11391739
    Abstract: Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 19, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ruben Carrasco, Di Zhu
  • Method for selecting individuals to be administered immune checkpoint inhibitor
    Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Bispecific CD3/CD19 polypeptide complexes
    Patent number: 11365254
    Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 21, 2022
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Jieying Liu, Jianqing Xu, Zhuozhi Wang, Qin Mei, Jing Li
  • Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist
    Patent number: 11359027
    Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: June 14, 2022
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sébastien Maury, José Cohen, Benoît Salomon, Sina Naserian, Mathieu Leclerc
  • Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
    Patent number: 11357839
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 14, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
    Patent number: 11359021
    Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 14, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiaoling Gu, Jiahua Jiang, Lei Zhang, Qiyue Hu, Jinming Gu, Weikang Tao
  • L2A5 antibody or functional fragment thereof against tumour antigens
    Patent number: 11353460
    Abstract: This invention provides an antibody or functional antibody fragments, or probe thereof directed against a unique group of antigens identified in cancer. The present invention comprises nucleotide sequences derived from L2A5 monoclonal antibody. The antibody or functional antibody fragment, or probe thereof includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. This DNA/amino acid sequence conjugation is unique and has never been described before. The present invention further provides antibody or functional antibody fragment or a conjugate or a recombinant protein useful in the detection, treatment and prevention of human disease, including cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 7, 2022
    Assignees: UNIVERSIDADE NOVA DE LISBOA, INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FG, EPE, HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF—INSTITUTE OF RADIOPHARMACEUTICAL CANCER RESEARCH
    Inventors: Paula Alexandra Quintela Videira, Carlos Manuel Mendes Novo, Liliana Raquel Rodrigues Loureiro, Mylène Adelaide do Rosário Carrascal, José Alexandre Ribeiro de Castro Ferreira, Maria Angelina de Sá Palma, Lúcio Lara Santos, Luís Carlos Oliveira Lima, Wengang Chai, Michael Bachmann
  • Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof
    Patent number: 11345754
    Abstract: A monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. A humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 31, 2022
    Assignee: AcroImmune Biopharma Co., Ltd.
    Inventors: Hongqun Hu, Zui Chen, Xiaoqi Song, Shiping Luo, Mingwen Cai, Jinling Fan, Yiqing Xu, Qunmin Zhou
  • Bispecific antigen-binding constructs targeting Her2
    Patent number: 11325981
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Biomarkers of therapeutic responsiveness
    Patent number: 11327076
    Abstract: The present invention relates to methods of diagnosing breast cancer in a patient, as well as methods of monitoring the progression of breast cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: May 10, 2022
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Simone Barbero, Eli N. Glezer, Anu Mathew
  • Immunogenic peptides of SCD1 protein
    Patent number: 11318185
    Abstract: The present invention addresses the problem of finding a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 3 to 45; or (b) a polypeptide comprising one to several amino acid deletions, substitutions or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • IgG binding peptides and multifunctional antigen-binding proteins comprising the same
    Patent number: 11312784
    Abstract: Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-binding proteins, vectors containing the disclosed polynucleotides, and cells that have been genetically engineered to express the polynucleotide are also provided. Methods of using the multifunctional antigen-binding proteins are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 26, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Hongtao Zhang, Zhiqiang Zhu, Lian Lam, Zheng Cai
  • In vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
    Patent number: 11300569
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignees: ISERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • CMET monoclonal binding agents, drug conjugates thereof and uses thereof
    Patent number: 11299547
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 12, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Vincent Blot, Marco Gymnopoulos, Anjuli Timmer, Ryo Fujita, Roland Newman
  • Compositions and methods for treatment of diseases involving CXCL1 function
    Patent number: 11292832
    Abstract: The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: April 5, 2022
    Inventor: Charles J. Rosser
  • Antihuman PCSK9 monoclonal antibody and application thereof
    Patent number: 11286309
    Abstract: The invention discloses a brand-new PCSK9 antibody. The PCSK9 antibody is sieved through a phage display technology, then a full-length gene sequence is obtained through a gene engineering technology, and applied to preparation of the antibody, and the prepared antibody is high in yield and short in period and is a humanized antibody. The invention further discloses an anti-tumor effect of the antihuman PCSK9 antibody, which expands the way of thinking for research on occurrence and development of tumors in the future, and lays foundations for preparing the antihuman PCSK9 antibody into monoclonal antibody medicines used for treating tumors in the later period.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: March 29, 2022
    Assignee: ZHEJIANG BLUE SHIELD PHARMACEUTICAL CO., LTD.
    Inventors: Zhigang Guo, Li Jing, Ali Wajid
  • Cell based anti-cancer compositions with reduced toxicity and methods of making the same
    Patent number: 11286308
    Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: March 29, 2022
    Assignee: Thomas Jefferson University
    Inventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
  • Anti-CD112R compositions and methods
    Patent number: 11279758
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 22, 2022
    Assignee: Surface Oncology, Inc.
    Inventors: Bianka Prinz, Nadthakarn Boland, Kevin Schutz, John Bukowski, Jennifer Symonds, James Mohan, Marisella Panduro Sicheva